Cargando…
Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease
Phosphorylated alpha-synuclein (p-alpha-syn) deposits, one of the neuropathological hallmarks of Parkinson’s disease (PD), have recently been detected in dermal nerve fibres in PD patients with good specificity and sensitivity. Here, we studied whether p-alpha-syn may serve as a biomarker in patient...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348554/ https://www.ncbi.nlm.nih.gov/pubmed/28180961 http://dx.doi.org/10.1007/s00401-017-1684-z |
_version_ | 1782514254452097024 |
---|---|
author | Doppler, Kathrin Jentschke, Hanna-Maria Schulmeyer, Lena Vadasz, David Janzen, Annette Luster, Markus Höffken, Helmut Mayer, Geert Brumberg, Joachim Booij, Jan Musacchio, Thomas Klebe, Stephan Sittig-Wiegand, Elisabeth Volkmann, Jens Sommer, Claudia Oertel, Wolfgang H. |
author_facet | Doppler, Kathrin Jentschke, Hanna-Maria Schulmeyer, Lena Vadasz, David Janzen, Annette Luster, Markus Höffken, Helmut Mayer, Geert Brumberg, Joachim Booij, Jan Musacchio, Thomas Klebe, Stephan Sittig-Wiegand, Elisabeth Volkmann, Jens Sommer, Claudia Oertel, Wolfgang H. |
author_sort | Doppler, Kathrin |
collection | PubMed |
description | Phosphorylated alpha-synuclein (p-alpha-syn) deposits, one of the neuropathological hallmarks of Parkinson’s disease (PD), have recently been detected in dermal nerve fibres in PD patients with good specificity and sensitivity. Here, we studied whether p-alpha-syn may serve as a biomarker in patients with a high risk of developing PD, such as those with REM sleep behaviour disorder (RBD). We compared the presence and distribution of p-alpha-syn deposits in dermal nerve fibres in 18 patients with RBD, 25 patients with early PD and 20 normal controls. Skin biopsy was taken at C7, Th10, and the upper and lower leg. Presynaptic dopamine transporter imaging using FP-CIT-SPECT was performed in all patients with RBD and in 11 patients with PD. All RBD patients underwent olfactory function testing. The likelihood ratio (LR) for prodromal PD was calculated for each patient based on published research criteria. Skin serial sections were assessed by double-immunofluorescence labelling with antibodies to pSer129-alpha-syn under blinded conditions. P-alpha-syn was visualized in 10/18 patients with RBD (sensitivity of 55.6%) and in 20/25 early PD patients (sensitivity of 80%) but in none of the controls (specificity of 100%). The percentage of dermal structures innervated by p-alpha-syn-positive fibres was negatively correlated with dopamine transporter binding in the FP-CIT-SPECT (ρ = −0.377, p = 0.048), with olfactory function (ρ = −0.668, p = 0.002), and positively correlated with the total LR for RBD to present prodromal PD (ρ = 0.531, p = 0.023). Dermal p-alpha-syn can be considered a peripheral histopathological marker of synucleinopathy and can be detected in a subgroup of RBD patients presumably representing prodromal PD. Dermal p-alpha-syn is detectable in RBD patients without PD motor symptoms, thereby stratifying a patient group that is of great interest for clinical trials testing disease-modifying drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-017-1684-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5348554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-53485542017-03-27 Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease Doppler, Kathrin Jentschke, Hanna-Maria Schulmeyer, Lena Vadasz, David Janzen, Annette Luster, Markus Höffken, Helmut Mayer, Geert Brumberg, Joachim Booij, Jan Musacchio, Thomas Klebe, Stephan Sittig-Wiegand, Elisabeth Volkmann, Jens Sommer, Claudia Oertel, Wolfgang H. Acta Neuropathol Original Paper Phosphorylated alpha-synuclein (p-alpha-syn) deposits, one of the neuropathological hallmarks of Parkinson’s disease (PD), have recently been detected in dermal nerve fibres in PD patients with good specificity and sensitivity. Here, we studied whether p-alpha-syn may serve as a biomarker in patients with a high risk of developing PD, such as those with REM sleep behaviour disorder (RBD). We compared the presence and distribution of p-alpha-syn deposits in dermal nerve fibres in 18 patients with RBD, 25 patients with early PD and 20 normal controls. Skin biopsy was taken at C7, Th10, and the upper and lower leg. Presynaptic dopamine transporter imaging using FP-CIT-SPECT was performed in all patients with RBD and in 11 patients with PD. All RBD patients underwent olfactory function testing. The likelihood ratio (LR) for prodromal PD was calculated for each patient based on published research criteria. Skin serial sections were assessed by double-immunofluorescence labelling with antibodies to pSer129-alpha-syn under blinded conditions. P-alpha-syn was visualized in 10/18 patients with RBD (sensitivity of 55.6%) and in 20/25 early PD patients (sensitivity of 80%) but in none of the controls (specificity of 100%). The percentage of dermal structures innervated by p-alpha-syn-positive fibres was negatively correlated with dopamine transporter binding in the FP-CIT-SPECT (ρ = −0.377, p = 0.048), with olfactory function (ρ = −0.668, p = 0.002), and positively correlated with the total LR for RBD to present prodromal PD (ρ = 0.531, p = 0.023). Dermal p-alpha-syn can be considered a peripheral histopathological marker of synucleinopathy and can be detected in a subgroup of RBD patients presumably representing prodromal PD. Dermal p-alpha-syn is detectable in RBD patients without PD motor symptoms, thereby stratifying a patient group that is of great interest for clinical trials testing disease-modifying drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-017-1684-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-02-08 2017 /pmc/articles/PMC5348554/ /pubmed/28180961 http://dx.doi.org/10.1007/s00401-017-1684-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Doppler, Kathrin Jentschke, Hanna-Maria Schulmeyer, Lena Vadasz, David Janzen, Annette Luster, Markus Höffken, Helmut Mayer, Geert Brumberg, Joachim Booij, Jan Musacchio, Thomas Klebe, Stephan Sittig-Wiegand, Elisabeth Volkmann, Jens Sommer, Claudia Oertel, Wolfgang H. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease |
title | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease |
title_full | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease |
title_fullStr | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease |
title_full_unstemmed | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease |
title_short | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease |
title_sort | dermal phospho-alpha-synuclein deposits confirm rem sleep behaviour disorder as prodromal parkinson’s disease |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348554/ https://www.ncbi.nlm.nih.gov/pubmed/28180961 http://dx.doi.org/10.1007/s00401-017-1684-z |
work_keys_str_mv | AT dopplerkathrin dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT jentschkehannamaria dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT schulmeyerlena dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT vadaszdavid dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT janzenannette dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT lustermarkus dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT hoffkenhelmut dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT mayergeert dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT brumbergjoachim dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT booijjan dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT musacchiothomas dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT klebestephan dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT sittigwiegandelisabeth dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT volkmannjens dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT sommerclaudia dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease AT oertelwolfgangh dermalphosphoalphasynucleindepositsconfirmremsleepbehaviourdisorderasprodromalparkinsonsdisease |